[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
Interferon beta-1b has been shown to reduce the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (MS). Unrealistic expectations of the patient and unexpected side effects may lead to discontinuation of the drug. Here we provide guidelines how to inform the patient adequately before therapy and discuss the most common side effects of interferon therapy.
Walther
E U
EU
Neurologische Klinik und Poliklinik, Klinikum Grosshadern, München.
Dietrich
E
E
Hohlfeld
R
R
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D001772:Blood Cell Count; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage* / Q000009:adverse effects; D008111:Liver Function Tests; D008297:Male; D009103:Multiple Sclerosis / Q000628:therapy*; D009460:Neurologic Examination / Q000187:drug effects; D010353:Patient Education as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
D000276:Adjuvants, Immunologic; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a
Therapie der multiplen Sklerose mit Interferon-beta-1b. Aufklärung des Patienten und Umgang mit Nebenwirkungen.